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The current leading Zika vaccine candidates in clinical testing are based on live or killed virus
platforms, which have safety issues, especially in pregnant women. Zika subunit vaccines,
however, have shown poor performance in preclinical studies, most likely because the
antigens tested do not display critical quaternary structure epitopes present on Zika E protein
homodimers that cover the surface of the virus. Here, we produce stable recombinant E
protein homodimers that are recognized by strongly neutralizing Zika specific monoclonal
antibodies. In mice, the dimeric antigen stimulate strongly neutralizing antibodies that target
epitopes that are similar to epitopes recognized by human antibodies following natural Zika
virus infection. The monomer antigen stimulates low levels of E-domain III targeting neu-
tralizing antibodies. In a Zika challenge model, only E dimer antigen stimulates protective
antibodies, not the monomer. These results highlight the importance of mimicking the highly
structured flavivirus surface when designing subunit vaccines.
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Zika virus (ZIKV) is an enveloped single stranded RNAvirus that is transmitted by mosquito vectors. As a memberof the flavivirus genus, ZIKV shares many structural fea-
tures with other medically important flaviviruses such as Wes
Nile virus, yellow fever virus, and dengue virus (DENV). The
flavivirus envelope (E) protein is a major target of neutralizing
and protective human antibodies. E oligomers form complex
quaternary structure epitopes on the viral surface which are of
particular importance as protective human antibodies bind to
these higher order protein structures1.
ZIKV infection during pregnancy can result in neurodevelop-
mental defects (congenital Zika syndrome). This has stimulated
work on subunit vaccines, as live attenuated and other replicating
virus vaccines are contraindicated during pregnancy. However,
for flaviviruses subunit vaccines based on recombinant E proteins
(rE) have performed poorly in preclinical studies compared with
virus or virus-like particle (VLP) vaccines2–6. In aqueous solution,
flavivirus rE proteins are in a dynamic equilibrium that favors the
monomer over the dimer at physiological temperature, which
likely explains poor binding by potently neutralizing human
antibodies targeting quaternary epitopes and the overall poor
immunogenicity of these antigens in preclinical studies2,7,8.
Here, we investigate if ZIKV rE dimers are better subunit
vaccine antigens than monomers. Unlike the E monomer, the
dimer is recognized by strongly neutralizing mAbs isolated from
ZIKV patients and the dimer, not the monomer, stimulates
strongly neutralizing and protective antibodies that targeted
epitopes that were similar to epitopes recognized by human
antibodies following natural Zika virus infection. These results
highlight the importance of mimicking the highly structured
flavivirus surface when designing subunit vaccines. The flavivirus
field has a long history of using E monomers as vaccine antigens
with limited success. These results highlight the importance of
mimicking the highly structured flavivirus surface when design-
ing subunit vaccines, and are applicable to developing second
generation subunit vaccines against Zika as well as other medi-
cally important flaviviruses like dengue and yellow fever.
Results
Expression of ZIKV rE monomers and homodimers. Here, to
investigate if ZIKV rE dimers are better subunit vaccine antigens
than monomers, we expressed ZIKV rE variants (aa1–402) that are
monomers (rEM) or stable dimers (rED) under physiological
conditions. We generated stable ZIKV rED proteins as previously
described for DENV E protein by introducing a disulfide bridge
(A264C) in the E-domain II interactive region of the
homodimer9,10 (Fig. 1a). The oligomeric state of the purified rEM
and rED proteins were confirmed by protein gel electrophoresis
(Fig. 1b). The stable rED, but not the rEM, was efficiently recognized
by neutralizing mAbs that have dimer-dependent quaternary
footprints, such as ZIKV-specific mAbs A9E, G9E, and ZKA-230
and flavivirus cross-reactive mAbs C8 and C10 (Fig. 1c).
ZIKV rED, but not rEM, induces neutralizing antibodies. After
confirming that rED was a dimer displaying native quaternary
epitopes, we immunized C57BL/6 mice with 5 µg rEM, 5 µg rED,
5 µg rEM+alum, or 5 µg rED+alum and analyzed ZIKV-specific
IgG and neutralizing antibody titers over time (Fig. 2a). In the
absence of alum, rEM and rED induced minimal IgG titers after
the initial immunization, but this response increased upon
boosting (Fig. 2b, c). In the alum adjuvanted groups, high IgG
titers were observed even after the prime alone, with minimal
change upon boosting (Fig. 2b). Although rEM elicited ZIKV-
binding antibodies in the absence of alumn, these antibodies
failed to neutralize ZIKV (Fig. 2d). In contrast, non-adjuvanted
rED elicited ZIKV-neutralizing antibodies (Fig. 2d). The addition
of alum adjuvant elevated neutralizing antibody levels in both
groups, but neutralizing titers were significantly higher after rED
immunization compared with rEM. Our results demonstrate that,
while both antigens stimulated ZIKV-specific IgG, the rED sti-
mulated antibodies that are more potently neutralizing compared
with the rEM stimulated antibodies.
ZIKV rED stimulates antibodies that target complex epitopes.
We next performed experiments to determine if antibodies stimu-
lated by rEM and rED antigens recognized different epitopes on the
ZIKV E protein. Many flavivirus type-specific antibodies recognize
relatively simple epitopes on domain III of the E protein (EDIII),
whereas other type-specific antibodies recognize more complex
quaternary structure epitopes displayed on E protein homodimers
or higher order structures that cover the viral surface. Most EDIII-
specific neutralizing antibodies have been isolated from mice
immunized with inactivated flavivirus antigens11–13. In contrast,
most quaternary epitope directed neutralizing antibodies have been
isolated from people infected with wild-type flaviviruses7,14–17. In














































Fig. 1 Expression pf ZIKV rE monomers and rE homodimers. a The soluble ZIKV rE-monomer (rEM, aa1–404) was expressed and purified from mammalian
cells. The soluble stable ZIKV rE-homodimer (rED) was generated by an A264C substitution, resulting in a disulfide bridge in the E-domain II dimer
interphase (yellow). b Purified rEM and rED were analyzed by SDS-PAGE and exhibited predicted molecular weights of ~49 kDa (monomer) and ~98 kDa
(dimer). c Binding of ZIKV specific (A9E, G9E, and ZKA-230) and flavivirus cross-reactive (4G2, 1M7, C8, and C10) mAbs to ZIKV rEM and rED was
analyzed. Binding of mAbs that have a quaternary footprint (Q) was only observed for rED. The DENV2 specific mAb 2D22 was used as a negative control.
Results from n= 2 independent experiments are shown. Error bars represent standard deviation. Source data are provided as a Source Data file
people exposed to flavivirus infections or effective live attenuated
vaccines predominantly recognize quaternary epitopes, with simple
EDIII epitopes accounting for only a minor fraction of neutralizing
antibodies18–22. To compare levels of EDIII directed antibodies in
animals immunized with rEM or rED, we used recombinant ZIKV-
EDIII conjugated to magnetic beads to deplete mouse immune sera
of EDIII-binding antibodies (Fig. 3a). We tested control-depleted
and EDIII antibody depleted immune sera to estimate the levels of
binding (Fig. 3b) and neutralizing antibodies (Fig. 3c) in each
sample targeting epitopes on EDIII. In mice immunized with rEM,
~70% (rEM group) and ~60% (rEM+alum group) of total ZIKV-
specific IgG recognized epitopes on EDIII (Fig. 3b). On the other
hand, significantly less EDIII-specific antibodies were induced after
immunization with rED (~30% for rED and ~20% for rED+alum).
The antibody binding patterns were also reflected in the ZIKV
neutralization assays. The majority of neutralizing antibodies in the
rEM+alum group were lost following depletion with EDIII antigen
(Fig. 3c). In contrast, no loss of neutralization was observed in the
animals immunized with rED or rED+alum after the removal of
EDIII-binding antibodies (Fig. 3c). We conclude that the rEM
antigen induces an EDIII focused antibody response that is poorly
neutralizing, whereas rED antigens stimulate robust neutralizing
antibody responses that target epitopes distinct from simple EDIII
epitopes.
We recently isolated two ZIKV-specific strongly neutralizing
human mAbs (A9E and G9E) from a person who was infected
with ZIKV in 201623. These antibodies map to complex epitopes
on domain I (A9E) and domain II (G9E) of ZIKV E protein23.
Moreover, antibody blockade assays using these mAbs and
human immune sera indicated that the epitopes targeted by these
mAbs also are targeted by antibodies in immune serum from Zika
patients but not dengue patients23. We used a blockade of binding
(BOB) assay to test if mice immunized with rEM or rED
developed antibodies that recognize A9E or G9E epitopes on
ZIKV. We also tested if rEM or rED antigens stimulated
antibodies that targeted the epitope of human mAb EDE C1017
which binds to a E dimer-dependent epitope that is conserved
between DENV and ZIKV. Sera from mice immunized with rEM
did not block binding of A9E, G9E, and C10 mAbs to ZIKV
(Fig. 3d). In contrast, sera from mice immunized with rED
antigen efficiently blocked binding of A9E and G9E (~80%) and
partially blocked binding of EDE C10 (~35%) to ZIKV. These
results demonstrate that the rED antigen and natural ZIKV
infections stimulate antibodies that target similar complex
epitopes on the virion. The rEM fails to induce similar antibodies
and directs the antibody response to simple epitopes on
ZIKV EDIII.
ZIKV rED induces protective antibodies in mice. Next, we
investigated if the immune sera of mice vaccinated with rEM
+alum and rED+alum could protect mice from lethal ZIKV
challenge. We immunized wild-type mice as previously descri-
bed (Fig. 2), and transferred heat-inactivated immune sera to
Ifnar1−/− mice which are highly susceptible to ZIKV. Ifnar1−/−
mice were challenged with 1000 FFU of ZIKV H/PF/2013, 1 day
post serum transfer. Mice were monitored for weight loss and
ZIKV induced disease, and mice were bled at days 0 (before
virus challenge), 4, and 14 (Fig. 4a). The potently neutralizing
mAb G9E was used as a positive control for protection against
ZIKV infection23. Mice that received G9E or serum from rED
+alum immunization were completely protected against weight
loss and disease signs. In contrast, mice receiving rEM+alum
serum exhibited significant weight loss and hindlimb paralysis
(Fig. 4b). At 4 days post challenge, viremia levels in the rED
+alum group were significantly reduced compared with the rEM
+alum and vehicle groups (Fig. 4c), and all groups cleared
viremia at day 14. We also measured ZIKV-specific IgG titers
(Fig. 4d) and neutralizing antibody titers (Fig. 4e) at days 0 and
14. Mice receiving rEM+alum and rED+alum immune sera
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Fig. 2 ZIKV rED induces neutralizing antibody responses. a Mice were primed with 5 µg of ZIKV rEM or rED (+/−alum) and boosted with similar doses at
weeks 3 and 9. Mice were bled (b) at indicated time points (n= 5 for rEM, rED, rEM+alum, and rED+alum, and n= 3 for vehicle control). b ZIKV-specific
single point dilution (1:50) IgG titers were determined by virus capture ELISA. c ZIKV-specific endpoint dilution (EPD) titers were determined at week 16 by
virus capture ELISA; EPD is the serum dilution at which detection signal equals background levels. d ZIKV-neutralizing activity at week 16 was determined
on Vero cells and expressed as the serum dilution at which 50% of the virus was neutralized (Neut50). Statistical differences were determined by one-way
ANOVA followed by a Tukey’s test (*p < 0.05). Data points represent individual mice. Error bars represent standard deviation. Source data are provided as
a Source Data file
marginally higher for both groups at day 14. On the other hand,
neutralizing antibody titers were higher at day 14 in the rEM
+alum group, likely caused by an endogenous immune response
elicited against replicating virus in these animals (Fig. 4c).
Discussion
The magnitude, sudden onset and severe clinical manifestations
of ZIKV epidemics highlight the need for safe and effective
vaccines for key patient populations including pregnant women.
While effective live attenuated vaccines have been developed for
several flaviviruses, they are contraindicated in pregnant women.
Live vaccines typically are ineffective during the first year of life
because maternal antibodies interfere with vaccine replication. It
has been difficult to formulate tetravalent live attenuated DENV
vaccines that stimulate balanced and effective responses to each
serotype because of differential replication of vaccine virus
components. Subunit vaccines may address some of these chal-
lenges, but progress has been slow and subunit vaccines have not
performed well in non-human primate models24. Our studies
offer a potential explanation for the poor performance of subunit
vaccines and a strategy for developing more effective flavivirus
vaccines. Our results demonstrate that a critical aspect of rE
antigen design is to develop E proteins that display complex
quaternary epitopes that recapitulate antigen presentation on the
surface of infectious virus particles. Here we demonstrate that
ZIKV rEM and rED subunit antigens induce antibody responses
that differ in functionality and domain focus. ZIKV rE monomers
stimulated an EDIII biased, poorly neutralizing IgG response. In
contrast, ZIKV rE dimers induced strongly neutralizing and
protective antibodies that also blocked the binding of strongly
neutralizing human mAbs to quaternary epitopes on ZIKV.
While finer mapping studies are required to comprehensively
map the specificity of rED stimulated antibodies, our studies
suggest that by designing the E protein to be a stable homodimer,
it is possible to induce strongly neutralizing and protective anti-
bodies that mimic properties of protective antibodies induced by
natural infection. It is possible that inactivated whole virus or
virus-like particle (VLP) vaccines will also stimulate antibodies to
quaternary structure epitopes. An advantage to using rED-protein
subunits over inactivated virion or VLP vaccines is the absence or
prM protein in subunit vaccine but not virus or VLP vaccines.
PrM antibodies are non-neutralizing and some studies suggest
that enhance the replication of flaviviruses25. Additional studies
are needed to compare the immunogenicity, efficacy and safety of
ZIKV rE-dimer, inactivated virus and VLP vaccines. The strategy
we describe here for ZIKV E protein may also be applicable for
developing subunit vaccines against other medically significant
flaviviruses.
Methods
Cells and viruses. Vero-81 cells (ATCC CCL-81) were maintained in DMEM
medium (Gibco)+ 1% non-essential amino acids, 5% fetal bovine serum, strep-
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Fig. 3 ZIKV rED stimulates antibodies that target complex epitopes on the virion. aMethod for depleting EDIII-binding antibodies from mouse immune sera.
Recombinant ZIKV E-domain III (EDIII, His-tagged) was coupled to nickel beadsi then incubated with immune seraii. Magnetic pull down removes nickel
beads and EDIII-binding antibodiesiii, leaving behind sera depleted from EDIII-binding antibodiesiv. b The level of EDIII-binding antibodies in the serum of
mice immunized with the indicated antigens is shown as a percentage of the total level of ZIKV-specific IgG, as measured by ELISA of EDIII-depleted and
control-depleted serum. c The neutralizing activity of EDIII-depleted (green) and undepleted sera (black) was determined and expressed as the dilution at
which 50% of the virus was neutralized (Neut50). d A blockade of binding (BOB) assay was used to evaluate if mice immunized with rEM (black) or rED
(gray) developed antibodies that blocked the binding of A9E, G9E, and EDE C10 human mAbs. Data points represent individual mice. Statistical differences
were determined by one-way ANOVA followed by a Tukey’s test (*p < 0.05). Source data are provided as a Source Data file
Suspension adapted EXPI293 cells (ThermoFisher) were cultured in EXPI293
expression medium (Life Technologies). ZIKV strain H/PF/2013 was grown in
Vero cells and titered by focus-forming assay using flavivirus mAb E6026,27.
Production of ZIKV rE antigens. The recombinant ZIKV E (H/PF/2013; aa1–404)
monomers (rEM) and stable E dimers (rED) were expressed in the EXPI293
transient expression system (ThermoFisher) following supplied protocols. The rED
was created by an A264C substitution in E-domain II and all proteins were
equipped with a C-terminal 6 × His-tag. Recombinant proteins were purified as
previously described28. In short, cell supernatants were concentrated by tangential
filtration and proteins were affinity purified using Ni2+-chromatography columns.
Pooled elution fractions were subjected to size exclusion chromatography and
purified protein samples were flash frozen and stored at −80 °C.
Production of ZIKV EDIII proteins. ZIKA virus EDIII (H/PF/2013, aa302–403)
was expressed as an N-terminal MBP fusion protein equipped with a C-terminal
6 × His-tag in BL21–E. coli. Cells were transformed with a pET21-MBP/ZIKVEDIII
expression plasmid and expanded overnight to 100 ml cultures (LB-growth med-
ium, supplemented with 100 µg per ml ampicillin). Overnight cultures were
transferred to 1L LB-growth medium and grown to and OD600= 0.6 at 37 °C,
shaking at 225 rpm. ZIKV EDIII expression was stimulated by adding 50 mM
IPTG and cells were grown overnight at 16 °C with shaking at 225 rpm. Next, cells
were pelleted and lysed by high pressure homogenization. ZIKV EDIII proteins
were purified from the lysate by Ni2+-affinity chromatography. Eluted fractions
(50 mM Tris, 10 mM NaCl, 10% glycerol, 10% sucrose, pH 7.0) were pooled
and dialyzed overnight at 4 °C in 20 mM Tris, 50 mM NaCl, pH 7.0 and stored at
−80 °C.
Protein analysis. The oligomeric state of purified rEM and rED proteins was
characterized by ELISA and SDS-PAGE followed by Coomassie Brilliant Blue
(CBB) staining. For SDS-PAGE, 1 µg of rEM and rED were incubated in denaturing
gel loading buffer for 10 min at 95 °C. After centrifugation, proteins were separated
by SDS-PAGE and gels (original gel in Source Data File) were incubated with
CBB stain (0.1% coomassie blue, 10% acetic acid, 50% methanol). Protein con-
firmations were analyzed by antigen-capture ELISA. ZIKV rEM and rED were
captured on Ni2+-coated ELISA plates and subjected to binding of ZIKV-specific 2
ng per µl mAbs (A9E, G9E, and ZKA-230)23 and flavivirus cross-reactive mAbs
(4G2 and 1M7)16,29.
Mouse immunizations and challenge. Female C57BL/6 mice were purchased
from Jackson Laboratory and used for immunizations at 6–12 weeks of age.
Female A129 (B6.129S2-Ifnar1tm1Agt/Mmjax) mice were purchased from
MMRRC (Mutant Mouse Resource & Research centers supported by NIH) and
used in challenge experiments at 7 weeks of age. All mouse experiments were
performed under protocols approved by the University of North Carolina
Institutional Animal Care and Use Committee, in compliance with ethical and
federal regulations (the Public Health Service Policy on Humane Care and Use of
Laboratory Animals, Animal Welfare Act, and the Guide for the Care and Use of
Laboratory Animals).
For evaluation of ZIKV rE immunogenicity, mice were immunized
subcutaneously in the flank with 5 µg soluble rEM (n= 5), 5 µg rEM+ 500 µg alum
(Alhydrogel, Invivogen) (n= 5), 5 µg rED (n= 5), 5 µg rED+ 500 µg alum (n= 5),
or PBS (n= 3). All groups received three immunizations (day 0, 21, and 63), and
serum samples were collected on day 21, 28, 70, 77, 84, 91, 98, 105, and 112 by
submandibular bleed.
To evaluate the protective activity of rE-induced antibodies, heat-inactivated
immune sera were passively transferred to ZIKV susceptible A129 mice. Serum
samples (days 70 through 112) of mice immunized with rEM+ alum and rED+
alum (days 70–112) were pooled and 500 µl of immune sera (per mouse, n= 5), or
vehicle control serum (n= 3) was injected into A129 mice, via intraperitoneal
route 1 day prior to ZIKV challenge. The ZIKV-neutralizing mAb G9E23 was used
as a positive control (200 µg/mouse, n= 3). Mice were challenged with 1000 FFU of
ZIKV (H/PF/2013) by subcutaneous footpad inoculation. Mice were weighed daily
for 14 days and monitored for clinical disease signs. Mice losing 30% of their
starting weight were humanely euthanized.
ZIKV rE-induced antibody evaluation. ZIKV-specific IgG responses were mea-
sured by antigen-capture ELISA. Briefly, ZIKV was captured on 1M7 (2 ng per µl)-
coated ELISA plates and incubated with 1:50 or serially diluted mouse sera 3, 4, 10,
and 16 weeks post immunization. Next, plates were incubated with alkaline
phosphatase conjugated anti-mouse IgG (1:2500; Sigma A9044) diluted anti-mouse
IgG for 1 h at 37 °C. Wells were developed using alkaline phosphatase substrate and
adsorbance was measured at 405 nm. Endpoint dilution (EPD) titers where mice
sera signals reached background (vehicle control) levels was determined using
GraphPad Prism software.
Evaluation of neutralizing antibody responses. Neutralizing antibody titers were
determined using a flow cytometry based assay. Vero-81 cells were seeded (25,000
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Fig. 4 ZIKV rED induce protective antibodies in mice. a Wild-type mice were immunized with rEM+alum or rED+alum. Five hundred microliters of heat-
inactivated immune sera (16 weeks post immunization) (or 200 µg of neutralizing mAb G9E) was transferred by intraperitoneal injection to Ifnar1−/− mice
24 h prior to challenge with 1000 FFU of ZIKV by subcutaneous footpad inoculation (n= 5 for rEM and rED and n= 3 for controls). b Challenged mice were
weighed daily for 14 days; weights are shown percent of starting weight. Data represent the mean +/−SEM of 3–5 mice per group and were censored once
one mouse in a group died. c Viremia was measured at 4 days post challenge by qRT-PCR. d–e ZIKV-specific IgG and neutralizing antibody titers were
determined for challenged mice prior to challenge (day 0) and at the end of the experiment (day 14). Statistical differences were determined by one-way
ANOVA followed by a Tukey’s test (*p < 0.05). Source data are provided as a Source Data file
diluted in OptiMEM (Gibco) supplemented with 2% FBS and incubated for 45 min
at 37 °C with the amount of ZIKV previously determined to infect ~15% of the
cells. Cells were subsequently washed with OptiMEM and overlaid with the diluted
sera/virus mix for 2 h at 37 °C. Next, the cells were washed with growth medium
and incubated overnight in growth medium at 37 °C. The next day, cells were
washed with PBS and detached from the plate by trypsin (Gibco). Cells were
subsequently fixed in 4% paraformaldehyde and washed in permeabilization buffer
and blocked with 1% normal mouse serum in perm buffer for 30 min at room
temperature. Following incubation, infected cells were detected by staining with
Alexa-488 conjugated 1M7 mAb (5 µg per µl) for 1 h at 37 °C. Next, cells were
washed in perm buffer and resuspended in 200 µl FACS buffer. The percentage of
infected cells were determined using the Guava Flow Cytometer (EMD Millipore)
and the neutralizing capacity was expressed as neut50 (the dilution where 50% of
the virus is neutralized), calculated by GraphPad Prism software.
Depletion of EDIII-binding IgG from mouse serum. Bacterially expressed ZIKV
EDIII proteins (C-terminal 6 × His-tag) were conjugated to Ni-NTA Magnetic
beads (Thermo Scientific) following manufacturers protocol. In short, 1 mg of
Ni-NTA beads were washed in equilibration buffer and incubated on a rotator
with 60 µg of ZIKV-EDIII or MBP-His (control depletions) for 1 h at 37 °C.
Next, the beads were washed in equilibration buffer and divided in two tubes for
two rounds of depletions. Mouse immune serum was diluted 1:20 in PBS and
incubated with magnetic beads for 1 h at 37 °C on a rotator. Following incu-
bation, the depleted serum was separated from the beads and stored at 4 °C for
subsequent IgG ELISA and neutralization assays. The percentage of ZIKV EDIII-
binding antibodies was calculated by dividing the EDIII-depleted IgG titers by
the control-depleted IgG titers. The percentage of ZIKV EDIII neutralizing
antibodies was calculated by dividing the EDIII-depleted neut50 by the control-
depleted neut50.
Human mAb blockade of binding (BOB) assay. High-binding ELISA plates were
coated with 2 ng per µl 1M7 human mAb in PBS for 1 h at 37 °C. Next, plates were
blocked with 3% skim milk in PBS+ 0.05% Tween for 30 min at 37 °C. After
blocking, plates were washed in PBS+ 0.2% Tween and incubated with ZIKV
H/PF/2013 for 1 h at 37 °C. The plates were washed and incubated with serially
diluted immunized mouse sera for 1 h at 37 °C. Next, the plates were washed and
incubated with alkaline phosphatase (AP)-conjugated A9E, G9E or C10 human
mAb at 2 ng per µl for 1 h at 37 °C. Following incubation, the plates were washed
and developed with AP-substrate and absorbance was measured at 405 nm.
ZIKV RNA qRT-PCR analysis. Viral RNA was isolated from 30 µl of mouse sera
using the QIAmp Viral RNA Mini Kit (Qiagen) following manufacturer’s protocol.
RNA was eluted in RNase free MilliQ water and stored at −80 °C. For qRT-PCR, 2
µl of RNA was added to 18 µl of PCR mastermix (10 µl of iTaq universal probes
mix+ 0.5 µl of iScript advanced reverse transcriptase+ 2 µl of forward primer (10
µM; CATGATACTGCTGATTGC)+ 2 µl of reverse primer (10 µM; CCTTCCA-
CAAAGTCCCTATTGC)+ 0.4 µl of probe (IDT; 10 µM; FAM-CGGCATACA-
ZEN-GCATCAGGTGCATAGGAG-IBFQ)+ 6.5 µl of nuclease-free H2O). Next,
samples were analyzed in a Bio-Rad CFX96 Thermocycler according to the fol-
lowing program: 10 min at 50 °C, 2 min at 95 °C (10 s at 95 °C, 20 s at 60 °C) × 40
cycles. RNA was isolated from a known quantity of ZIKV H/PF/2013 to generate a
standard curve.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings of this study are available within
the paper. The source data underlying the figures are provided as a Source Data file.
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